Abstract:
Background: Rosuvastatin can decrease low-density lipoprotein cholesterol to the optimal goals. Adverse effects of rosuvastatin involve kidneys. Multiple studies explained that these side effects are due to reducing coenzyme Q10 levels.
Objective: to throw light upon the histological changes in the renal cortex of albino rats treated with rosuvastatin and explore the impact of CoQ10 co-treatment.
Methods: Forty adult albino rats were used in the study as follows: Group I: formed of 8 rats, given 1 ml distilled water/day for one month orally; Group II: formed of 8 rats, given 1.8 milligrams/Kilogram/day (CoQ10) for one month orally; Group III: formed of 8 rats, given 0.72 milligrams/Kilogram/day rosuvastatin for one month orally; Group IV: formed of 8 rats, given 0.72 milligrams/Kilogram/day rosuvastatin and 1.8 milligrams/Kilogram/day CoQ10 for one month orally; Group V: formed of 8 rats, received the same dose of rosuvastatin as in group III then the rats were sacrificed two weeks later.
Results: In group III, there were severe histo-pathological changes in the renal corpuscles and tubules. Also, the biochemical results (serum urea and creatinine) were deteriorated. In group V and IV, the biochemical results were improved significantly. The histological integrity of the renal cortex was returned to normal.
Conclusion: This study revealed that CoQ10 played a protective role against rosuvastatin nephrotoxicity.